Ryan Watts, Denali CEO

De­nali slips as a snap­shot of ear­ly da­ta rais­es some trou­bling ques­tions on its pi­o­neer­ing blood-brain bar­ri­er neu­ro work

De­nali Ther­a­peu­tics had drummed up con­sid­er­able hype for their blood-brain bar­ri­er tech­nol­o­gy since launch­ing over six years ago, hype that’s on­ly in­ten­si­fied in the last 14 months fol­low­ing the pub­li­ca­tions of a pair of pa­pers last spring and proof of con­cept da­ta ear­li­er this year. On Sun­day, the South San Fran­cis­co-based biotech gave the bio­phar­ma world the next look at in-hu­man da­ta for its lead can­di­date in Hunter syn­drome.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.